An Open-Label, Two-Period, Randomized, Single Oral Dose, Crossover Study to Evaluate the Bioequivalence of Tasimelteon Capsule Formulation Relative to Tasimelteon Liquid Suspension Formulation in Healthy Volunteers
Latest Information Update: 25 Mar 2024
Price :
$35 *
At a glance
- Drugs Tasimelteon (Primary)
- Indications Circadian rhythm sleep disorders; Pervasive child development disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Vanda Pharmaceuticals
- 19 Mar 2024 Status changed from active, no longer recruiting to completed.
- 11 Oct 2022 New trial record